Geneva, May 16 -- International Clinical Trials Registry received information related to the study (ACTRN12625000438459) titled 'A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1' on May 12 2025.
Study Type: Interventional
Study Design:
Purpose: Treatment; Allocation: Non-randomised trial; Assignment: Other;
Primary Sponsor: Australasian Myeloma Research Consortium
Condition: Myeloma;Multiple myeloma;Relapsed refractory myeloma; Myeloma Multiple myeloma Relapsed refractory myeloma;Cancer - Myeloma
Intervention:
Each treatment cycle is 28-days. Maximum number of cycles is 24. Treatment is administered by hospital staff.[Talquetamab] - To be given subcutaneously- Cycle 1 Day 1 -0.01mg per kg- Cycle 1 D...